HSTA 10-K & 10-Q changes, risk factors and insider trading
Hestia Insight Inc. · OTC · Services-Management Consulting Services · CIK 1813603 · All filings on SEC.gov
At a glance
What changed in the latest 10-K
Risk Factors
New heading “Subsequent Event – Closure of Subsidiary”
Largest changes
“Subsequent to December 31, 2025, the Company determined to discontinue the operations of one of its wholly owned subsidiaries, HSTA Health. The decision to cease operations was made as part of the Company’s strategic evaluation of its business activities.”see in full comparison
Full comparison: every changed paragraph (4)
The Company is an Emerging Growth CompanyCompany.
Subsequent Event – Closure of Subsidiary
Subsequent to December 31, 2025, the Company determined to discontinue the operations of one of its wholly owned subsidiaries, HSTA Health. The decision to cease operations was made as part of the Company’s strategic evaluation of its business activities.
Our strategic consulting and capital market advisory services will be affected by the current COVID-19 pandemicpandemic.
Management's Discussion & Analysis (MD&A)
New heading “A Strategic Shift to Artificial Intelligence”
New heading “A. Pre-Raise Strategy and Asset Building”
New heading “B. Market Research, Financials and White Papers for a Fundraise”
New heading “C. Investor Materials Preparation”
New heading “D. Investor Outreach and Investor Relations”
New heading “Discontinuation of Legacy Operations”
New heading “Board Approval to Raise Capital”
New heading “Focus on Growth and Innovation”
New heading “Executive Compensation”
Removed heading “Sales and Marketing”
Removed heading “Competitive Advantages”
Largest changes
“A Strategic Shift to Artificial Intelligence”see in full comparison
Full comparison: every changed paragraph (43)
A Strategic Shift to Artificial Intelligence
Hestia Insight Inc. has made the strategic decision to evolve into a full-fledged Artificial Intelligence (AI) technology company. This transformation will position Hestia Insight to develop and commercialize AI-powered solutions for business consulting and capital market advisory services.
The Company’s new AI product offerings will focus on enhancing key areas of business development, with particular emphasis on comprehensive fundraising support through our AI Enhanced Fundraising Services. Similar AI-driven services are also being developed by the Company for other sectors including Healthcare, Fintech and Legal Tech.
A. Pre-Raise Strategy and Asset Building
B. Market Research, Financials and White Papers for a Fundraise
C. Investor Materials Preparation
D. Investor Outreach and Investor Relations
In addition to developing proprietary AI products, Hestia Insight will aggressively seek to license or represent other exceptional products in its focus areas. This approach is designed to offer clients a more comprehensive and versatile suite of products and services, helping them succeed across all stages of business growth.
Through its AI technology platform, Hestia Insight aims to assist startups, small businesses, and growth-stage companies in accelerating their go-to-market strategies and preparing for investment readiness in a rapidly evolving digital economy.
Discontinuation of Legacy Operations
In alignment with this shift, Hestia Insight will discontinue its legacy operations in:
This move allows the company to streamline resources and focus on high-growth potential opportunities in AI product development and intellectual property-based consulting.
Board Approval to Raise Capital
To support the company’s strategic transformation, Hestia Insight’s Board of Directors has approved a capital raise of up to $5 million. This will be executed through a combination of equity offerings and/or convertible debt instruments.
Proceeds will be allocated toward:
This funding initiative is a critical step in positioning Hestia Insight as a market leader in AI-based business advisory services.
Focus on Growth and Innovation
With a renewed mission and sharpened focus, Hestia Insight is committed to delivering innovative, data-driven solutions that empower entrepreneurs, investors, and organizations to achieve scalable success in today’s competitive marketplace.
Overview
Hestia Insight Inc. (“Hestia”, “Hestia Insight”, or the “Company”) was incorporated in the State of Nevada on November 19, 2003, under the name Luxshmi Investments, Inc. (“Luxshmi Investments”), until the Company changed its name to Hestia Insight Inc. on March 27, 2019. On March 12, 2019, the Company filed a Certificate of Amendment to its Articles of Incorporation authorizing 300,000,000 shares of capital stock, comprised of 290,000,000 shares of common stock, par value $0.001 per share (the “Common Stock”) and 10,000,000 shares of preferred stock, par value $0.00001 per share (the “Preferred Stock”). On March 27, 2019, the Company filed a Certificate of Amendment to its Articles of Incorporation (i) effecting a name change from Luxshmi Investments, Inc. to Hestia Insight Inc., and (ii) effecting a 50-to-1 reverse stock split of the Company’s issued and outstanding shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split did not impact the Company’s authorized shares of Common Stock or Preferred Stock, or its par value. On May 16, 2019, the Company entered into a Share Exchange Agreement with Hestia Investments Inc., a Wyoming corporation (“Hestia Investments”), to exchange, on a 1-for-1 basis, 27,614,200 shares of the Company’s Common Stock in exchange for 27,614,200 shares of Hestia Investments which were owned by 100% of the then-shareholders of Hestia Investments (the “Share Exchange Transaction”). As a result of the Share Exchange Transaction, Hestia Investments became a wholly owned subsidiary of the Company.
Business Model
The Company is focused primarily on the healthcare
and biotech sectors through the Company’s two wholly owned operating subsidiaries, Hestia Investments Inc. (“Hestia Investments”),
and HSTA HEALTH INC., d/b/a Hestia Vending (“Hestia Vending”). Hestia Investments provides strategic consulting, medical
supply sales and marketing support, management, and capital markets advisory services for select micro, small and medium sized companies
within the healthcare and biotech sectors. Hestia Vending operates within the healthy food, beverage and wellness products industry and
the smart vending machine industry.
The Company’s wholly owned operating subsidiary,
Hestia Vending, operates within the healthy food, beverage and wellness products industry and the smart vending machine industry. On July 11,
2023, Hestia Vending entered into a Vending Purchase Agreement with HealthyYOU Vending LLC (“HealthyYou”) pursuant to which
the Company purchased from HealthyYou ten (10) fully automated vending machines and related equipment (the “Vending Machines”)
for an aggregate purchase price of $98,745.00, in connection with the Company’s vending pilot program. The technologically advanced,
unattended Vending Machines dispense healthy food and wellness products to paying customers at the point of sale, accepting cash, coin,
credit or debit cards, and payments by smartphones, watches and other devices. The Company’s goal is to create a technology-driven
health and wellness vending business division through its purchase and operation of the Vending Machines. In addition, on September 24,
2023, Hestia Vending entered into a strategic partnership with ChargerGoGo, Inc. (“ChargerGoGo”), a Las Vegas-based company
which operates one of the largest portable phone charging networks in the US. Hestia Vending plans to introduce ChargerGoGo smart phone
charging station and power bank kiosks in densely populated locations and venues for smart phone charging convenience. ChargerGoGo smart
phone charging stations and power banks allow users to obtain a portable battery from any ChargerGoGo kiosk, charge their smart phones,
and avoid missing an important event or meeting. ChargerGoGo portable batteries are then returned by users to any nearby ChargerGoGo kiosk.
Hestia Investments is a corporate advisory firm specializing in the
biotech and healthcare sectors, offering comprehensive services to both private and public companies, focusing on U.S. capital markets
transactions and investment opportunities across various industries. Its expertise encompasses business operations, corporate finance,
mergers and acquisitions, and guiding companies through the process of going public in the United States. By integrating into its clients'
operations, Hestia Investments provides tailored and effective advisory services. Additionally, Hestia Investments assist in identifying
suitable exit strategies, including strategic acquisitions, mergers, and initial public offerings.
In addition, the Company intends to pursue the acquisition
and development of healthcare-related technologies in the healthcare and biotech sectors through acquisition, licensing or joint ventures.
We will also consider a third avenue of investing in certain technologies. The Company entered the healthcare sector to explore emerging
healthcare technologies, especially growth companies that own and develop unique sciences and technologies.
Sales and Marketing
We seek to develop new business through relationships driven by our senior management, which have extensive contacts throughout the healthcare system. Our senior management is seeking opportunities for joint ventures, strategic relationships and acquisitions in the healthcare and biotech sectors.
The Company intends to pursue the acquisition and development of healthcare-related technologies in the healthcare and biotech sectors through acquisition, licensing or joint ventures. We will also consider a third avenue of investing in certain technologies. The Company entered the healthcare sector to explore emerging healthcare technologies, especially growth companies that own and develop unique sciences and technologies.
Competitive Advantages
The Company focuses on small and micro-cap companies
in the healthcare and biotech sectors with limited access to growth capital. We provide specialized consulting services to assist companies
with their operations in the public markets. Our management team is experienced in risk management and exit planning. The Company’s
competitive advantages include a global business network of healthcare, investment and financial professionals who are integrated into
the technology licensing and commercialization departments of universities and institutions. Through our offered services and access
to investment, we intend to accelerate the development and commercialization of the healthcare businesses that we engage with.
Executive Compensation
On June 10, 2025, the Board of Directors of Hestia Insight Inc. determined that it is in the best interest of the Company to formalize compensation arrangements for its Chief Executive Officer.
Accordingly, the Board approved a compensation package for the Company’s Chief Executive Officer, Edward C. Lee, effective immediately. The approved compensation structure includes an annual base salary of $100,000, payable in accordance with the Company’s standard payroll practices and/or in the form of equivalent value of the Company’s common stock, as determined by the Board from time to time.
In addition to the base salary, the Chief Executive Officer may be eligible for bonus or performance-based incentives, stock options or other equity-based awards, and additional benefits, the terms and conditions of which are to be determined by the Board of Directors in accordance with the Company’s compensation policies and applicable governance standards.
During the year ended November 30, 2024,
2025, total revenues amounted to $1,249,884.$8,000. For the year ended November 30, 2023,2024, revenue was $113,413.$1,249,884. The increasedecrease of $1,136,471$1,241,884 in
revenue was due to an increasedecrease in consulting revenue.
For the years ended November 30, 2025, 2024, 2023,
general and administrative expenses were $398,355$312,919 and $415,061,$398,355, respectively. The decline in general and administrative expenses amount
was largely due to a reduction in professional fees to $ 99,137 for the year ended November 30, 2025 compared to professional fees of
$ to $126,804 for the year ended November 30, 2024 compared to professional fees of
$244,312 for the year ended November 30, 2023.2024.
During the year ended November 30, 20232025 the Company
sold certain fixed assets and recognized a loss of $74,889.($20,277). There were no sales of fixed assets during the year ended November 30, 2024.
Operating activities used $134,272 in cash for the year ended November 30, 2025, as compared with using $168,805 for the year ended November 30, 2024.
Operating activities used $168,805 in cash for the
year ended November 30, 2024, as compared with using $278,214 for the year ended November 30, 2023. These uses of cash from
operating activities are mainly the result from the receipt of equity securities as payment for services provided income of $1,147,884
for the year ended November 30, 2024, and a net loss of $(500,405) for the year ended November 30, 2023.
For the year ended November 30, 2024, the
Company used $16,198 to purchase investment equities and received $53,345 from the sale of investment equities.
For the year ended November 30, 2023, the
Company used $30,125 to purchase investment equities and received $103,658 from the sale of investment equities.
For the year ended November 30, 2024,2025, the
Company received $78,931$112,500 of net cash for financing activities, and for the year ended November 30, 2023,2024, the Company was provided
$-0- $78,931 of cash flow from financing activities.
The Company’s financial statements have
been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in
the normal course of business. The Company generated net Losses of ($943,444) for the year ended November 30, 2025, and a net income
of $642,205 for the year ended November 30, 2024, and a net loss
of $500,405 for the year ended November 30, 2023.2024. The Company had accumulated deficits of $114,323$1,057,766 and $756,528$114,322 as of November 30,
20242025 and 2023,2024, respectively. These factors, among others, raise substantial doubt about the Company’s ability to continue as a
going going
concern.
What changed in the latest 10-Q
Risk Factors
Our business, financial condition, results of operations, and cash flows may be impacted by a number of factors, many of which are beyond our control, including those set forth in our most recent Annual Report on Form 10-K for the year ended November 30, 2025, the occurrence of any one of which could have a material adverse effect on our actual results. There have been no material changes to the Risk Factors previously disclosed in our Annual Report on Form 10-K for the year ended November 30, 2025.
No wording changes found in this section.
Full comparison: every changed paragraph (0)
Management's Discussion & Analysis (MD&A)
Largest changes
“The guidance in ASC 321 allows a measurement exception for those equity investments that do not have a “readily determinable fair value,” as defined therein, and do not qualify to be measured using the practical expedient to estimate fair value at net asset value (NAV) of the investee in accordance with ASC 820-1035-59, Fair Value Measurement and Disclosure. …”see in full comparison
We have a limited operating history, and our continuedsee in full comparisoncontinuedgrowth is dependent upon the continuation of providing medical consulting services to our clients, generating revenue, and obtaining additional financing to fund future obligations, and pay liabilities arising from normal business operations. We had accumulated deficits of $(1,054,6181,536,740) atFebruaryMay28,31, 2026. The report of our independent registered public accounting firm on our financial statements for the year ended November 30, 2025, contained an explanatory paragraph regarding our ability to continue as a going concern based upon cash used in operating activities and the current cash balance cannot be projected to cover the operating expenses for the next twelve months from the release date of this report. These factors, among others, raised substantial doubt about our ability to continue as a going concern. Our financial statements appearing elsewhere in this reportdo not include any adjustments that might result from the outcome of this uncertainty. There are no assurances we will be successful in our efforts to generate significant revenues or report profitable operations or to continue as a going concern, in which event investors would lose their entire investment in our company. The financial statements contained hereindo not include any adjustments that might result from the outcome of this uncertainty. There are no assurances we will be successful in our efforts to generate significant revenues or report profitable operations or to continue as a going concern, in which event investors would lose their entire investment in our company. The financial statements contained herein do not include any adjustments that might result from the outcome of this uncertainty.
Comparison of Results of Operations for the sixsee in full comparisonThree Monthsmonths endedFebruaryMay28,31, 2026, andFebruaryMay28,31, 2025
“In August 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This ASU addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. …”see in full comparison
Cost of revenue includes the cost of internal laborsee in full comparisonlabourand related benefits, travel expenses related to consulting services, subcontractor costs, other related consulting costs, and other overhead costs. These costs are recorded as operating expenses. For thethreesix months endedFebruaryMay28,31, 2026, andFebruaryMay28,31, 2025, there were no costs of revenue.
Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations and otherwise operate on an ongoing basis. Onsee in full comparisonFebruaryMay28,2026,31,2026, and November 30. 2025, we had cash and cash equivalent balances of$17,084$19,141 and $28,871, respectively. These funds are kept in financial institutionsinstitutionslocated in United States. We had total liabilities of$309,088$835,682 onFebruaryMay28,31, 2026, of which$92,656$85,081 for accounts payable and accruedaccruedliabilities and$216,431$233,931 for a related party note payable and $16,670 for a short-term loans from shareholders and officer payable $500,000 and a Federal Income taxes payable $0. We had total liabilities of $278,245 on November 30, 2025, of which $86,814 is for accounts payable and accruedliabilities.liabilities and $173,931 is payable to a related party. As ofFebruaryMay28,31, 2026, and November30.30, 2025, the Company had accumulatedearnings/(deficits) of $(1,054,6181,536,741) and $(1,057,766), respectively.
Full comparison: every changed paragraph (25)
The following discussion and analysis of the
results results
of operations and financial condition of Hestia Insight Inc. for the threesix months ended FebruaryMay 28,31, 2026, and FebruaryMay 28,31,
2025, should be read in conjunction with the Hestia Insight Inc. unaudited consolidatedCondensed Consolidated financial statements and the notes
thereto contained
elsewhere in this report. Our discussion includes forward-looking statements based upon current expectations that
involve risks and uncertainties,
such as our plans, objectives, expectations and intentions. Actual results and the timing of events
could differ materially from those
anticipated in these forward-looking statements as a result of a number of factors, including
those set forth under the Risk Factors,
Special Note Regarding Forward-Looking Statements and Business sections in our Form 10-K as
filed with the Securities and Exchange Commission
on MarchMay 14,02, 2024.2026. We use words such as “anticipate,”
“estimate,” “plan,” “project,”
“continuing,” “ongoing,”
“expect,” “believe,” “intend,” “may,”
“will,” “should,”
“could,” and similar expressions to identify forward-looking statements.
Hestia Insight is positioned to make strategic acquisitions
acquisitions of emerging growth companies with unique sciences and technologies and actively seeks licensing opportunities for exceptional products
products that complement our AI-powered service offerings. Through acquisition, licensing, joint ventures, and direct investment, we continue to
to build a comprehensive ecosystem of business development and capital markets solutions. For more information about Hestia Insight, please
visit the Company’s website: www.hestiainsight.comwww.hestiainsight.com.
We have a limited operating history, and our continued
continued growth is dependent upon the continuation of providing medical consulting services to our clients, generating revenue, and
obtaining additional
financing to fund future obligations, and pay liabilities arising from normal business operations. We had accumulated
deficits of $(1,054,6181,536,740)
at FebruaryMay 28,31, 2026. The report of our independent registered public accounting firm on our financial
statements for the year ended November 30,
2025, contained an explanatory paragraph regarding our ability to continue as a going
concern based upon cash used in operating activities
and the current cash balance cannot be projected to cover the operating expenses
for the next twelve months from the release date of this
report. These factors, among others, raised substantial doubt about our ability
to continue as a going concern. Our financial statements
appearing elsewhere in this report do not include any adjustments that might
result from the outcome of this uncertainty. There are no assurances we will be successful in our efforts to generate significant revenues
or report profitable operations or to continue as a going concern, in which event investors would lose their entire investment in our
company. The financial statements contained herein do not include any adjustments that might result from the outcome of this uncertainty. There are no
assurances we will be successful in our efforts to generate significant revenues or report profitable operations or to continue as a going
concern, in which event investors would lose their entire investment in our company. The financial statements contained herein do not
include any adjustments that might result from the outcome of this uncertainty.
Our discussion and analysis of our financial
condition condition
and results of operations are based upon our consolidatedCondensed Consolidated financial statements, which have been prepared in
accordance with accounting
principles generally accepted in the United States. The preparation of these consolidatedCondensed Consolidated
financial statements requires us to make estimates
and judgments that affect the reported amounts of assets, liabilities, revenues
and expenses, and related disclosure of contingent assets
and liabilities. We continually evaluate our estimates, including those
related to bad debts, recovery of long-lived assets, income taxes
and the valuation of equity transactions.
We base our estimates on historical experience and
and on various other assumptions that we believed to be reasonable under the circumstances, the results of which form the basis for making
judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to
these estimates and assumptions could cause a material change to our reported amounts of revenues, expenses, assets and liabilities. Actual
results may differ from these estimates under different assumptions or conditions. We believe the following critical accounting policies
affect our more significant judgments and estimates used in the preparation of the consolidatedCondensed Consolidated financial statements.
Effective December 1, 2017, the Company adopted Accounting Standards Update (“ASU”) 2016-01 “Financial Instruments—Recognition and Measurement of Financial Assets and Financial Liabilities.” ASU 2016-01 adds a new Topic, “ASC 321 Investments – Equity Securities” to the FASB Accounting Standards Codification, which provides guidance on accounting for all equity investments.
The guidance in ASC 321 allows a measurement exception for those equity investments that do not have a “readily determinable fair value,” as defined therein, and do not qualify to be measured using the practical expedient to estimate fair value at net asset value (NAV) of the investee in accordance with ASC 820-1035-59, Fair Value Measurement and Disclosure. The measurement alternative allows those investments to be measured at their cost minus impairment, if any, plus or minus changes resulting from observable price changes in “orderly transactions,” as defined, for the identical or a similar investment of the same issuer. Hestia has elected to use this measurement exception. See Note 3 below for a detailed listing of the Company’s investment in equities to which the measurement exception applies.
In August 2016, the Financial Accounting
Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-15, Statement of Cash Flows (Topic 230):
Classification of Certain Cash Receipts and Cash Payments. This ASU addresses the classification of certain specific cash flow issues
including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after
a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees.
This ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early
adoption permitted. An entity that elects early adoption must adopt all of the amendments in the same period. We are currently evaluating
the impact it may have on our consolidated financial statements.
Other accounting standards that have been issued
or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on our consolidated financial
statements upon adoption. We do not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to our
consolidated financial condition, results of operations, cash flows or disclosures.
Comparison of Results of Operations for the six
Three Monthsmonths ended FebruaryMay 28,31, 2026, and FebruaryMay 28,31, 2025
For the threesix months ended FebruaryMay 28,31, 2026,
total revenues
is zero.$16,000. For the threesix months ended FebruaryMay 28,31, 2025, revenue was zero,$0, all of which consisted of consulting revenue.
The limited amount of
revenue was due to our current emphasis on planning and preparation for our future revenue.
Cost of revenue includes the cost of internal labor
labour and related benefits, travel expenses related to consulting services, subcontractor costs, other related consulting costs, and
other overhead
costs. These costs are recorded as operating expenses. For the threesix months ended FebruaryMay 28,31, 2026, and FebruaryMay 28,
31, 2025, there were no costs
of revenue.
For the threesix months ended FebruaryMay 28,31, 2026 operating expenses
expenses were $39,326$576,401 representing an decreaseincrease of $71,343$343,494 over the operating expenses of $110,669$232,907 for the threesix months ended February
28,May, 2025.2025 . This decrease increase
in operating expenses was mainly driven by aan decreaseincrease in professionalOfficer feesCompensation relatedfor tolast becoming5 and being a public
company plus our current emphasis on reducing costs.years.
For the threesix months ended FebruaryMay 28,31, 2026,
and February 28,May, 2025,
operating expenses consisted of the following:
As a result of the foregoing, for the threesix months
ended FebruaryMay 28,31, 2026, loss from operations amounted to $(39,326),$478,971, as compared to lossincome from operations of $(110,669644,757) for the threesix months
months ended FebruaryMay 28,31, 2025.
Other income includes gain/losses, dividends and
interest income/Bad debt Expense
from stock dividends and bank deposits that amounted to $42,478$0 and $281,626,$75, for the threesix months ended
February 28,May 31, 2026 and FebruaryMay 28,31, 2025, respectively.
The Company had realized gains on equity investments
of $0 for the three months ended February 28, 2026 and& $435 for the threesix months ended FebruaryMay 28,31, 2025.2026 and May 31, 2025, respectively.
The Company had unrealized gains on equity investments
of $45,781$88,195 for the threesix months ended FebruaryMay 28,31, 2026, and unrealized losses on equity investments of $259,500$387,416 for the threesix months
ended February 28,May
31, 2025. For the threesix months ended FebruaryMay 28,31, 2026,2026 and FebruaryMay 28,31, 2025, therespectively, Company $-0-had salesloss of capital$0 assets& ($14,203) on sale of Capital
forAsset each period.respectively.
The Company had $3,303$6,766 interest expense for the
threesix months ended FebruaryMay 28,31, 2026 and $1,773($4,080) interest expense for the threesix months ended FebruaryMay 28,31, 2025. Company also had bad debt expense of
($6,660) in the period ended May 31, 2025.
We did not have any income tax expense for the
threesix months ended FebruaryMay 28,31, 2026 and FebruaryMay 28,31, 2025, since we did not have any taxable income in the periods which was not reduced
by prior
net operating loss carry forwards or reduced by the exclusion of any unrealized gains/(losses) on equity investments, which are excluded
excluded from our taxable income until they become realized gains/(losses) on equity investments.
The net income/loss for the threesix months ended May 31,
2026, was $478,971 and the net loss for the threesix months ended FebruaryMay 28, 2026 was $3,152 and February 28,31, 2025, was $(392,295).$644,757.
Liquidity is the ability of a company to generate
funds to support
its current and future operations, satisfy its obligations and otherwise operate on an ongoing basis. On FebruaryMay 28,2026, 31,2026,
and November
30. 2025, we had cash and cash equivalent balances of $17,084$19,141 and $28,871, respectively. These funds are kept in financial
institutions institutions
located in United States. We had total liabilities of $309,088$835,682 on FebruaryMay 28,31, 2026, of which $92,656$85,081 for accounts payable and
accrued accrued
liabilities and $216,431$233,931 for a related party note payable and $16,670 for a short-term loans from shareholders and officer payable
$500,000 and a Federal Income taxes payable $0. We had total liabilities of $278,245
on November 30, 2025, of which $86,814 is for accounts
payable and accrued liabilities.liabilities and $173,931 is payable to a related party. As of FebruaryMay 28,31, 2026, and November 30.30, 2025,
the Company had
accumulated earnings/(deficits) of $(1,054,6181,536,741) and $(1,057,766), respectively.
Operating activities used $(36,78768,900) in cash during
the threesix months ended FebruaryMay 28,31, 2026 as compared with using $(36,04764,676) in cash during the threesix months ended FebruaryMay 28,31, 2025. The
increase in cash
used in operating activities during the threesix months ended FebruaryMay 28,31, 2026, is primarily due to the increase consulting income and the decrease
in operating
expenses described above.
For the threesix months ended FebruaryMay 28,31, 2026,
the cash flows
in investing activities provided $0 in proceeds used in the purchase of investment equities.
For the threesix months ended FebruaryMay 28,31, 2026,
the Company
received $25,000$59,170 in proceeds provided by a related party loan. For the threesix months ended FebruaryMay 28,31, 2025, the Company received
$25,000 $50,000 in
proceeds provided by a related party loan.
HSTA insider buying and selling (Form 4)
Since 2026-04-11, insiders reported open-market purchases in 0 Form 4 filings and open-market sales in 0 filings. Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.
No Form 4 stock transactions in this period.
Well-known investors holding HSTA (13F)
None of the 59 investors we track reported a position in their latest 13F.